Brought to you by 
Series A round brings $15mm to Vivace Therapeutics
30 Jun 2017
Executive Summary
Vivace Therapeutics Inc. raised $15mm through a Series A round from founding investors Canaan Ventures and WuXi Healthcare Ventures, plus one additional undisclosed investor. The company is developing small molecule therapies and biologics for cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A round brings $15mm to Vivace Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice